There is now overwhelming evidence to support lowering LDL-c (low-density lipoprotein
cholesterol) to reduce cardiovascular morbidity and mortality. Statins are a class of drugs …

The nutraceutical market is currently a high-impact multi-billion-dollar industry, and it is
anticipated to grow rapidly over the next decade. Nutraceuticals comprise diverse food …

Berberine, an isoquinoline alkaloid isolated from the Chinese herb Coptis chinensis and
other Berberis plants, has a wide range of pharmacological properties. Berberine can be …

Moreover, over the last few years the approach to treatment of patients with a high
cardiovascular risk has totally changed from treatment aimed at a specific risk factor (ie …

Cardiovascular and metabolic diseases (CVMD) are the leading causes of death worldwide,
underscoring the urgent necessity to develop new pharmacotherapies. Berberine (BBR) is …

Abstract Background and aims This European Atherosclerosis Society (EAS) Task Force
provides practical guidance for combination therapy for elevated low-density lipoprotein …

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Introduction: Nutraceuticals, up today, do not have a specific definition distinct from those of
other food-derived categories, eg food supplements, herbal products, pre and probiotics …

Background Although statins play a pivotal role in the prevention of atherosclerotic
cardiovascular disease, many patients fail to achieve recommended lipid levels due to statin …

Background Low-density lipoprotein cholesterol (LDL-C) causes atherosclerotic disease, as
demonstrated in experimental and epidemiological cohorts, randomised controlled trials …